Myriad RBM, Sanofi Partner to Identify CV Biomarkers in Diabetes Patients

Oct 25, 2016

|

NEW YORK (GenomeWeb) – Myriad RBM announced today that it has signed an agreement to help Sanofi measure cardiovascular risk biomarkers in the blood samples of patients in a Phase III trial of its type II diabetes therapy lixisenatide.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Try the Other Version

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

You Do Your Way

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

CRISPR Discussions

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

This Week in Science

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.

Main menu